Evaluation of Immunological Parameters in Diabetic Patients: Are These Patients Immunodeficient?
-
Zoleikha Moazezi
,
Azam Hosseinian
,
Ensiyeh Ahmad Moazam
,
Mohamed Bagher Eslami
,
Ezatollah Mosavi
,
Haleh Akhavan-Niaki
,
Ali Bijani
,
Nanette Schloot
,
Amrollah Mostafazadeh
Abstract
It has been widely thought that diabetic patients are prone to infections due to hyperglycemia induced immunodeficiency; the present study was designed to examine this opinion. In diabetic patients and normal control groups T-cell reactivity to hsp-60 molecule, tetanus toxoid recall antigen (TT) and phytohemagglutinin-A (PHA) mitogen were evaluated The number of circulating IFN-γ, IL-10 and IL-13 cytokine producing cells stimulated with above antigens or mitogen as well as the serum levels of Th1/Th2 type cytokines were determined. Total serum immunoglobulins (IgG, IgA, IgM), C3, C4 and CH50 were also measured. Diabetic patients showed a positive circulating T-cell reactivity to human recombinant hsp60 However, this reactivity was significantly lower in comparison to control group (p<0.001). All other examined factors were not significantly different between diabetic and normal subjects except for the number of IFN-γ and IL-13 producing cells in response to PHA stimulation, which was higher in control gtroup (p=0.006, 0.018, respectively). The mean serum concentration of IgA in diabetic patients was 245.86 ± 115.05 mg/dl versus 192.96 ± 105.33 mg/dl in healthy control group (p<0.018). We were not able to demonstrate any substantial mitigation in cellular arms of immune reaction to some prominent T-cell antigens and mitogens, as well as, in main parameters of humoral immunity of diabetic patients, thus, the common notion of believing that patients with diabetes suffering from immunodeficiency should be revised. It is much more appropriate that "altered immunity" is applied instead of "immunodeficiency" to explain the immunity condition in this group of patients.
1. Fitzenberger E, Boll M, Wenzel U. Impairment of the proteasome is crucial for glucose-induced lifespan reduction in the mev-1 mutant of Caenorhabditis elegans. Biochim Biophys Acta 2013; 1832(4):565-73.
2. Kuzuya T, Nakagawa S, Satoh J, Kanazawa Y, Iwamoto Y, Kobayashi M, et al. Report of the Committee on the classification and diagnostic criteria of diabetes mellitus. Diabetes Res Clin Pract 2002; 55(1):65-85.
3. Wild S, Roglic G, Green A, Sicree R, King H. Global prevalence of diabetes: estimates for the year 2000 and projections for 2030. Diabetes Care 2004; 27(5):1047-53.
4. Carpino PA, Goodwin B. Diabetes area participation analysis: a review of companies and targets described in the 2008-2010 patent literature. Expert Opin Ther Pat 2010; 20(12):1627-51.
5. Soory M. Hormone mediation of immune responses in the progression of diabetes, rheumatoid arthritis and periodontal diseases. Curr Drug Targets Immune Endocr Metabol Disord 2002; 2(1):13-25.
6. Tanaka Y. Immunosuppressive mechanisms in diabetes mellitus. Nippon Rinsho 2008; 66(12):2233-7.
7. Hostetter MK. Handicaps to host defense. Effects of hyperglycemia on C3 and Candida albicans. Diabetes1990; 39(3):271-5.
8. Geerlings SE, Hoepelman AI. Immune dysfunction in patients with diabetes mellitus (DM). FEMS Immunol Med Microbiol 1999; 26(3-4):259-65.
9. Tuberculosis in compromised hosts. Kekkaku 2003;78(11):717-22.
10. Andreasen AS, Pedersen-Skovsgaard T, Berg RM, Svendsen KD, Feldt-Rasmussen B, Pedersen BK, et al. Type 2 diabetes mellitus is associated with impaired cytokine response and adhesion molecule expression in human endotoxemia. Intensive Care Med 2010; 36(9):1548-55.
11. Komura T, Sakai Y, Honda M, Takamura T, Matsushima K, Kaneko S. CD14+ monocytes are vulnerable and functionally impaired under endoplasmic reticulum stress in patients with type 2 diabetes. Diabetes 2010;59(3):634-43.
12. Weigelt C, Rose B, Poschen U, Ziegler D, Friese G, Kempf K, et al. Immune mediators in patients with acute diabetic foot syndrome. Diabetes Care 2009; 32(8):1491-6.
13. Donath MY, Størling J, Maedler K, Mandrup-Poulsen T.Inflammatory mediators and islet beta-cell failure: a link between type 1 and type 2 diabetes. J Mol Med 2003;81(8):455-70.
14. Stentz FB, Kitabchi AE. Activated T lymphocytes in Type 2 diabetes: implications from in vitro studies. Curr Drug Targets 2003; 4(6):493-503.
15. Ghawil M, Tonutti E, Abusrewil S, Visentini D, Hadeed I, Miotti V, et al. Autoimmune thyroid disease in Libyan children and young adults with type 1 diabetes mellitus. Eur J Pediatr 2011; 170(8):983-7.
16. Maciver NJ, Jacobs SR, Wieman HL, Wofford JA, Coloff JL, Rathmell JC. Glucose metabolism in lymphocytes is a regulated process with significant effects on immune cell function and survival. J Leukoc Biol 2008; 84(4):949-57.
17. Dinarello CA. Interleukin-1 in the pathogenesis and treatment of inflammatory diseases. Blood 2011;117(14):3720-32.
18. Dinarello CA. Blocking interleukin-1β in acute and chronic autoinflammatory diseases. J Intern Med 2011;269(1):16-28.
19. MostafaZadeh A, Eslami MB, Schloot NC, Hanifi Moghaddam P, Kolb H. Detection of antihuman HSP60 antibody in patients with type 1 diabetes. J Babol Univ Med Sci 2003; 5(3):7-11.
20. Mostafazadeh A, Herder C, Haastert B, Hanifi- Moghaddam P, Schloot N, Koenig W, et al. Association of humoral immunity to human Hsp60 with the IL-6 gene polymorphism C-174G in patients with type 2 diabetes and controls. Horm Metab Res 2005; 37(4):257-63.
21. Atalay M, Oksala N, Lappalainen J, Laaksonen DE, Sen CK, Roy S. Heat shock proteins in diabetes and wound healing. Curr Protein Pept Sci 2009; 10(1):85-95.
22. Ohashi K, Burkart V, Flohé S, Kolb H. Cutting edge: heat shock protein 60 is a putative endogenous ligand of the toll-like receptor-4 complex. J Immunol 2000;164(2):558-61.
23. Chen W, Syldath U, Bellmann K, Burkart V, Kolb H.Human 60-kDa heat-shock protein: a danger signal to the innate immune system. J Immunol 1999; 162(6):3212-9.
24. Ricklin D, Lambris JD. Complement in immune and inflammatory disorders: therapeutic interventions. J Immunol 2013; 190(8):3839-47.
25. Miller LE, Ludke HR, Peacock JE,Tomar RH. Manual of Laboratory Immunology.UK:Lea&Febiger Ltd.1991:137-139.
26. Gonzalez-Quintela A, Alende R, Gude F, Campos J, Rey J, Meijide LM, et al. Serum levels of immunoglobulins (IgG, IgA, IgM) in a general adult population and their relationship with alcohol consumption, smoking and common metabolic abnormalities. Clin Exp Immunol 2008; 151(1):42-50.
27. Vaarala O, Atkinson MA, Neu J. The "perfect storm" for type 1 diabetes: the complex interplay between intestinal microbiota, gut permeability, and mucosal immunity. Diabetes 2008; 57(10):2555-62.
28. Furst DE. Serum immunoglobulins and risk of infection how low can you go? Semin Arthritis Rheum 2009;39(1):18-29.
29. Fernandez Gonzalez S, Jayasekera JP, Carroll MC.Complement and natural antibody are required in the long-term memory response to influenza virus. Vaccine 2008; 26(Suppl 8):I86-93.
30. Perschinka H, Mayr M, Millonig G, Mayerl C, van der Zee R, Morrison SG, et al. Cross-reactive B-cell epitopes of microbial and human heat shock protein 60/65 in atherosclerosis. Arterioscler Thromb Vasc Biol 2003;23(6):1060-5.
31. Richardson A, Schwager F, Landry SJ, Georgopoulos C.The importance of a mobile loop in regulating chaperonin/ co-chaperonin interaction: humans versus Escherichia coli. J Biol Chem 2001; 276(7):4981-7.
32. Handley HH, Yu J, Yu DT, Singh B, Gupta RS, Vaughan JH. Autoantibodies to human heat shock protein (hsp)60 may be induced by Escherichia coli groEL. Clin Exp Immunol 1996; 103(3):429-35.
33. Varbiro S, Biro A, Cervenak J, Cervenak L, Singh M, Banhidy F, et al. Human anti-60 kD heat shock protein autoantibodies are characterized by basic features of natural autoantibodies. Acta Physiol Hung 2010; 97(1):1-10.
34. Könen-Waisman S, Fridkin M, Cohen IR. Self and foreign 60-kilodalton heat shock protein T cell epitope peptides serve as immunogenic carriers for a T cell- independent sugar antigen. J Immunol 1995;154(11):5977-85.
35. Chuchawankul S, Khorana N, Poovorawan Y. Piperine inhibits cytokine production by human peripheral blood mononuclear cells. Genet Mol Res 2012; 11(1):617-27.
36. Jacobs SR, Herman CE, Maciver NJ, Wofford JA, Wieman HL, Hammen JJ, et al. Glucose uptake is limiting in T cell activation and requires CD28-mediated Akt-dependent and independent pathways. J Immunol 2008; 180(7):4476-86.
37. Aikawa J, Moretto KD, Denes F, Yamazaki RK, Freitas FA, Hirabara SM, et al. Glucose metabolism by lymphocytes, macrophages, and tumor cells from Walker 256 tumor-bearing rats supplemented with fish oil for one generation. Cell Biochem Funct 2008; 26(8):874-80.
38. Zheng Y, Delgoffe GM, Meyer CF, Chan W, Powell JD.Anergic T cells are metabolically anergic. J Immunol 2009; 183(10):6095-101.
39. Pozzilli P, Gale EA, Visalli N, Baroni M, Crovari P, Frighi V, et al. The immune response to influenza vaccination in diabetic patients. Diabetologia 1986;29(12):850-4.
40. Solomonova K, Damiyanova K, Damiyanova M, Betovska M.Active immunization against tetanus of children suffering with diabetes mellitus. Z Immunitatsforsch Immunobiol. 1976.151(1):383-90.
41. Liberatore RR Jr, Barbosa SF, Alkimin MG, Bellinati- Pires R, Florido MP, Isaac L, et al. Is immunity in diabetic patients influencing the susceptibilityto infections? Immunoglobulins, complement and phagocytic function in children and adolescents with type 1 diabetes mellitus. Pediatr Diabetes 2005; 6(4):206-12.
42. Joshi N, Caputo GM, Weitekamp MR, Karchemer AW.Infections in patients with diabetes mellitus. New Engl J Med 1999; 341(25):1906-12.
| Files | ||
| Issue | Vol 13, No 2 (2014) | |
| Section | Articles | |
| Keywords | ||
| Adaptive Immunity Complement System Proteins Cytokines Diabetes Mellitus Infection | ||
| Rights and permissions | |
|
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License. |
